Orexigen Gets Interim OK For $7.5M DIP To Fund Sale Process

Law360, Wilmington (March 13, 2018, 11:10 PM EDT) -- Bankrupt prescription weight-loss treatment maker Orexigen Therapeutics Inc. received interim approval Tuesday in Delaware for access to $7.5 million in debtor-in-possession financing as part of a larger $70 million package.

During a first-day hearing in Wilmington, debtor attorney Christopher R. Bryant of Hogan Lovells told the court the post-petition financing will be needed for the debtor to run a sale process and that the lending package was being proposed on a fully consensual basis following several weeks of negotiations with stakeholders.

“We’re pleased to report we’re...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.